Authors : Rod Ibara Okabande; Fylla-Onanga Koumou; Nestor Andzouana; Ferdinand Brel Emaniel Got; Berge Tsiba Ngokana; Junior Batsi Poati; Judicael Foundikila; Etienne Mokondjimobe; Benjamin Longo-Mbendza; Henri Germain Monabeka

Volume/Issue : Volume 11 - 2026, Issue 5 - May

Google Scholar : https://tinyurl.com/49sdtwja

Scribd : https://tinyurl.com/477yv42b

DOI : https://doi.org/10.38124/ijisrt/26May2007

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Cardiovascular diseases represent a significant public health problem worldwide, and sub-Saharan Africa is experiencing increasing prevalence of diabetes and hypertension, necessitating early diagnosis for improved management. Comparing traditional monitoring results with those of emerging biomarkers such as Lp-PLA2 could help refine surveillance measures, particularly for screening for these conditions. This explains the importance of this study, which analysed Lp-PLA2 expression in the population of Brazzaville. 533 patients were included in this study, divided into 326 apparently healthy subjects (51 of whom were diagnosed with hypertension, 25 with diabetes, and 4 with both hypertension and diabetes) and 207 subjects with pre-existing conditions (123 with hypertension and 84 with diabetes). Among these subjects with pre-existing conditions, we also screened for comorbidities, which allowed us to group our study population into 10 groups. The standard lipid profile compared to Lp-PLA2 levels in screened subjects showed no statistically significant difference between these groups for the standard lipid profile, while a statistically significant difference was found for Lp-PLA2 values, especially when these subjects had other risk factors. Lp-PLA2 appears to be better expressed during low-grade vascular inflammation, specifically during the formation of atherosclerotic plaques, than in conventional lipid profiles. Its use in preventive monitoring of the onset of cardiovascular disease is warranted.

Keywords : Lp-PLA2, Cardiovascular Diseases, Vascular Inflammation, Type 2 Diabetes and Hypertension.

References :

1. World Health Organization (WHO): "Maladies cardiovasculaires", Principaux faits (31 Juillet 2025). Données sur les 19,8 millions de décès (2022) et la prévalence mondiale. Consulter le 27 mars 2026.
2. Ossou-Nguiet PM, Doungou ND, Mpandzou GA et al. Troubles cognitifs et diabète de type 2 au Congo. AJNS. 2019; (38): 1992-2647.
3. Ikama SM, Nsitou BM, Bouénizabila E et Monabéka HG. Prévalence des lésions d'athérosclérose chez les patients diabétiques à Brazzaville, Congo. J Mal Vasc. 2014-Déc; 39 (6): 443-4.
4. Monabéka HG, Kimbally-Kaky G, Gombet T et al. Syndrome métabolique et prévalence des cardiopathies ischémiques au CHU de Brazzaville, Congo. Med mal met. 2012-février; 6(1): 75-79.
5. Eboka-Loumingou SR, Longo-Mbenza, Nkalla-Lambi M et al. Inflammatory biomarkers and prédiction of insulin resistance in congolese adults. Heliyon 2021-feb 2;7(2): e06139.
6. Bonnefont-Rousselot D. La Lp-PLA2, marqueur d’inflammation vasculaire et de vulnérabilité de la plaque d’athérosclérose. Ann Pharm Fr. 2016; 74(3): 190-7.
7. Irena Kostovska, Svetlana Cekovska, Katerina Tosheska’Traikosvska, Danica Labudovic et al. Rôle de la phospholipase A2 associée aux lipoproteins (Lp-PLA2) dans la prédiction et l’évaluation de la gravité de la maladie coronarienne chez les patients atteints de diabète de type 2. J MED Biochem. 2025; 44(7): 1458-1465.
8. Mohamed IN, Ishrat T, Fagan SC, El-Remessy AB. Role of inflammasome activation in the pathophysiology of vascular diseases of the neurovascular unit. Antioxid Redox Signal. 2015; 22: 1188-206.
9. Dennis EA, Cao J, Hsu Y-H, Magrioti V, Kokotos G. Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. Chem Rev. 2011; 111: 6130-85.
10. Tellis CC and Tselepis AD. Pathophysiological role and clinical significance of lipoprotein-associated phospholipase A₂ (Lp-PLA₂) bound to LDL and HDL. Curr Pharm Des. 2014; 20: 6256-69.
11. Tselepis AD and Chapman JM. Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atheroscler Suppl 2002; 3: 57-68.
12. Huang F, Wang K, and Shen J. Lipoprotein-associated phospholipase A2: The story continues. Med Res Rev. 2020; 40: 79-134.
13. Edward W. Gregg, Naomi Holman, MarisaSophiea. Multiple long-term conditions as the next transition in the global diabetes epidemic. Communications Medicine. 2025; 5: 42.
14. American Diabetes Association. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2025. Diabetes Care 2025 ; 48(1) :27–49.
15. Isis T Silva, Ana PQ Mello and Nágila RT Damasceno. Antioxidant and inflammatory aspects of lipoprotein-associated phospholipase A2 (Lp-PLA2) : areview. Lipids in Health and Disease 2011, 10 :170.
16. Tiia Kekäläinen, Johanna Ahola, Emmi Reinilä, Tiina Savikangas, Marja-Liisa Kinnunen, Tuuli Pitkänen, Katja Kokko. Associations cumulatives entre les comportements liés à la santé, le bien-être mental et la santé sur 30 ans. Annales de médecine, 2025; 57 (1)
17. Bonaldi C., Grave C.  Serra D., Rogel A., Guignard R., Nguyen-thanh V. Les décès attribuables au tabagisme. Mise à jour des estimations pour l’année 2023. Édition national publiée le 16 février 2026. Site internet: Santé publique France. Saint-Maurice (France); 2026 [consulté le 06 Mai 2026]
18. Produits du tabac, produits connexes, arômes pour cigarettes: les mineurs sont de plus en plus exposés au risque d'intoxication. Vigil Anses du 21 novembre 2023. Site internet Agence nationale de sécurité de l'alimentation, de l'environnement et du travail. Maisons-Alfort (France); 2023 [consulté le 10 juin 2025]
19. Portail national d'information pour les personnes âgées et leurs proches. Il n'y a pas d'âge pour arrêter de fumer. Site internet: pour-les-personnes-agees.gouv. Paris; 2022 [consulté le 06 Mai 2025]
20. François Paillard. Oméga-3 et risque cardiovasculaire. Presse Med Form 2024; 5: 140–144.
21. Nizar Daoussi, Imene Mahmoud, Mouna Aissi, Rafik Machraoui, Narjes Mokni, Samia Younes, Mahbouba Frih-Ayed. Marqueurs biologiques de l’inflammation et risque d’accident vasculaire cérébral ischémique après un accident ischémique transitoire. Revue Neurologique 2017; 173(2) : S168.
22. Ymène Nekaies, Sami Kelbousi, Mohsen Sakly, Nebil Attia et Bruno Baudin.  Oxidized LDL and oxidized LDL receptor are associated with proprotein-convertase-subtilisine/kexine type 9 in patients with type 2 diabetes. Rev Franc Labo 2022; 544: 57-63.
23. Dominique Bonnefont-Rousselot. La phospholipase A2 associée aux lipoprotéines (Lp-PLA2): biomarqueur pertinent et cible thérapeutique. Annales Pharmaceutiques Françaises. January 2025; 83(1): 45-57.